CR9562A - Anticuerpos anti-cd40 humanizados y sus metodos de uso - Google Patents

Anticuerpos anti-cd40 humanizados y sus metodos de uso

Info

Publication number
CR9562A
CR9562A CR9562A CR9562A CR9562A CR 9562 A CR9562 A CR 9562A CR 9562 A CR9562 A CR 9562A CR 9562 A CR9562 A CR 9562A CR 9562 A CR9562 A CR 9562A
Authority
CR
Costa Rica
Prior art keywords
methods
humanized antibodies
antigen
antibodies
expression
Prior art date
Application number
CR9562A
Other languages
English (en)
Inventor
Leonard G Presta
Lori Y O'connell
Svetlana O Doronina
Original Assignee
Genentech Inc
Seatle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452957&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9562(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Seatle Genetics Inc filed Critical Genentech Inc
Publication of CR9562A publication Critical patent/CR9562A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

Se proveen anticuerpos anti-CD40 humanizados y fragmentos de union de antigeno y metodos para tratar una enfermedad caracterizada por la expresion del antigeno CD40.
CR9562A 2005-05-26 2007-12-06 Anticuerpos anti-cd40 humanizados y sus metodos de uso CR9562A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68485305P 2005-05-26 2005-05-26

Publications (1)

Publication Number Publication Date
CR9562A true CR9562A (es) 2008-03-06

Family

ID=37452957

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9562A CR9562A (es) 2005-05-26 2007-12-06 Anticuerpos anti-cd40 humanizados y sus metodos de uso

Country Status (19)

Country Link
US (4) US8303955B2 (es)
EP (1) EP1885399B1 (es)
JP (1) JP5027804B2 (es)
KR (1) KR100991010B1 (es)
CN (1) CN101237882B (es)
AT (1) ATE485057T1 (es)
AU (1) AU2006249305B2 (es)
BR (1) BRPI0610470A2 (es)
CA (1) CA2609269C (es)
CR (1) CR9562A (es)
DE (1) DE602006017690D1 (es)
EC (1) ECSP078026A (es)
ES (1) ES2354865T3 (es)
IL (1) IL187594A0 (es)
MA (1) MA29595B1 (es)
NO (1) NO341793B1 (es)
PL (1) PL1885399T3 (es)
RU (1) RU2407544C2 (es)
WO (1) WO2006128103A2 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
JP5027804B2 (ja) * 2005-05-26 2012-09-19 シアトル ジェネティクス，インコーポレーテッド ヒト化抗ｃｄ４０抗体およびその使用方法
MX2008007140A (es) * 2005-12-09 2009-03-04 Seattle Genetics Inc Metodos para utilizar agentes de union a cd40.
AU2008207898B2 (en) * 2007-01-23 2012-05-03 Xencor, Inc Optimized CD40 antibodies and methods of using the same
JP5730576B2 (ja) 2007-11-07 2015-06-10 ジェネンテック， インコーポレイテッド 抗ｃｄ４０抗体による治療に対するｂ細胞リンパ腫の応答性を評価するための方法及び組成物
US8518410B2 (en) 2009-03-10 2013-08-27 Baylor Research Institute Fusion protein with HIV antigen
FR2942799B1 (fr) * 2009-03-06 2011-02-25 Lfb Biotechnologies Anticorps monoclonal anti-rhesus d
CA2754906C (en) 2009-03-10 2021-02-09 Baylor Research Institute Antigen presenting cell targeted fusion proteins comprising a linker for increased stability
WO2010104761A2 (en) 2009-03-10 2010-09-16 Baylor Research Institute Anti-cd40 antibodies and uses thereof
ES2605228T3 (es) 2009-04-18 2017-03-13 Genentech, Inc. Métodos para evaluar la capacidad de respuesta de un linfoma de células B al tratamiento con anticuerpos anti-CD40
US20130052194A1 (en) 2009-12-16 2013-02-28 The Trustees Of The University Of Pennsylvania Anti-prostate cancer antibodies and methods of detection and treatment of prostate cancer using the same
AR081750A1 (es) 2010-03-31 2012-10-17 Boehringer Ingelheim Int Anticuerpos anti-cd40
PT3556774T (pt) 2011-03-11 2024-02-29 Beth Israel Deaconess Medical Ct Inc Anticorpos anti-cd40 e suas utilizações
EP2688592A4 (en) 2011-03-25 2015-07-22 Baylor Res Inst COMPOSITIONS AND METHODS FOR IMMUNIZATION AGAINST HEPATITIS C VIRUS
CN113461819B (zh) 2011-04-29 2024-01-02 埃派斯进有限公司 抗-cd40抗体及其使用方法
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
CA2851667A1 (en) * 2011-10-11 2013-04-18 Medimmune, Llc Cd40l-specific tn3-derived scaffolds and methods of use thereof
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP3925977A1 (en) 2012-10-30 2021-12-22 Apexigen, Inc. Anti-cd40 antibodies and methods of use
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
EP3094652B1 (en) 2014-01-13 2021-09-29 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
KR102632731B1 (ko) 2014-04-30 2024-02-01 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Ｃｄ269에 대한 인간화 항체
CR20170096A (es) 2014-08-12 2017-06-15 Alligator Bioscience Ab Tratamientos conjuntos con anticuerpos anti cd40
PT3212230T (pt) * 2014-10-29 2021-04-19 Seagen Inc Dosagem e administração de anticorpos anti-cd40 não fucosilados
CN107406503B (zh) * 2014-11-18 2021-07-16 詹森药业有限公司 Cd47抗体、方法和用途
TWI725966B (zh) 2015-04-13 2021-05-01 戊瑞治療有限公司 癌症組合療法
BR112018001907A2 (pt) * 2015-09-01 2018-09-25 Boehringer Ingelheim Int uso de anticorpos anti-cd40 para o tratamento de nefrite lúpica
MX2018002708A (es) 2015-09-04 2018-08-01 Primatope Therapeutics Inc Anticuerpos anti-cd40 humanizados y usos de los mismos.
MY196646A (en) 2015-09-30 2023-04-27 Janssen Biotech Inc Agonistic Antibodies Specifically Binding Human CD40 And Methods of use
US20170101471A1 (en) * 2015-10-08 2017-04-13 The Board Of Trustees Of The Leland Stanford Junior University Blockade of tim-1 for treating graft-versus-host disease
MX2018005550A (es) 2015-11-03 2019-07-18 Janssen Biotech Inc Anticuerpos que se unen especificamente a tim-3 y sus usos.
EA039944B1 (ru) * 2016-01-27 2022-03-30 Бёрингер Ингельхайм Интернациональ Гмбх Применение антител к cd40 для лечения волчаночного нефрита
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
IL263834B2 (en) 2016-06-20 2024-01-01 Kymab Ltd Antibodies against PD-L1
SG11201900746RA (en) 2016-08-12 2019-02-27 Janssen Biotech Inc Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
KR102554331B1 (ko) 2016-08-12 2023-07-10 얀센 바이오테크 인코포레이티드 향상된 효능적 활성을 갖는 Fc 조작된 항-TNFR 수퍼패밀리 구성원 항체 및 그의 사용 방법
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
EP3525813B1 (en) * 2016-10-11 2024-04-17 Razi Holdings, Inc. Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop
TWI763732B (zh) * 2016-11-07 2022-05-11 美商西雅圖遺傳學公司 工程化半胱胺酸帽之分佈
CN110546164B (zh) 2016-11-11 2023-10-20 锦湖Ht株式会社 特异性结合cd40的抗体及其用途
JP7304287B2 (ja) 2016-12-22 2023-07-06 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
MX2019011907A (es) * 2017-04-04 2020-01-09 Hoffmann La Roche Nuevas moleculas de union a antigeno biespecificas capaces de unirse especificamente a cd40 y a fap.
MX2019014375A (es) 2017-06-01 2020-01-23 Jiangsu Hengrui Medicine Co Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo.
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CN111182944B (zh) 2017-11-01 2022-11-22 豪夫迈·罗氏有限公司 双特异性2+1 Contorsbody
WO2019133747A1 (en) * 2017-12-27 2019-07-04 Bristol-Myers Squibb Company Anti-cd40 antibodies and uses thereof
JP2021528393A (ja) 2018-06-15 2021-10-21 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 後細胞シグナル伝達因子の調節による免疫活性の上昇
TW202023625A (zh) 2018-08-23 2020-07-01 美商西雅圖遺傳學公司 抗tigit抗體
PE20211863A1 (es) * 2018-10-01 2021-09-21 Hoffmann La Roche Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap
CN112654641A (zh) * 2018-10-01 2021-04-13 豪夫迈·罗氏有限公司 具有与cd40的三价结合的双特异性抗原结合分子
US20210355216A1 (en) 2018-10-05 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and systems for controlling the agonistic properties of antibody variable domains by light
MX2021006360A (es) 2018-11-30 2021-08-11 Jiangsu Hengrui Medicine Co Composicion farmaceutica de anticuerpo cd40 y uso de la misma.
TW202039558A (zh) 2018-11-30 2020-11-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｃｄ４０抗體、其抗原結合片段及其醫藥用途
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
WO2020253722A1 (en) * 2019-06-17 2020-12-24 Eucure (Beijing) Biopharma Co., Ltd Anti-cd40 antibodies and uses thereof
WO2021048135A1 (en) 2019-09-09 2021-03-18 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
TW202206100A (zh) 2020-04-27 2022-02-16 美商西健公司 癌症之治療
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
EP4221751A1 (en) 2020-09-30 2023-08-09 Seagen Inc. Uveal melanoma treatment using sea-cd40
IL302402A (en) 2020-11-08 2023-06-01 Seagen Inc Combined treatment
WO2022212784A1 (en) 2021-03-31 2022-10-06 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
WO2022251311A1 (en) 2021-05-25 2022-12-01 Seagen Inc. Methods of quantifying anti-cd40 antibodies
CN115403670A (zh) 2021-05-26 2022-11-29 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
EP4363059A1 (en) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023010080A1 (en) 2021-07-30 2023-02-02 Seagen Inc. Treatment for cancer
WO2023198851A1 (en) 2022-04-14 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5985847A (en) * 1993-08-26 1999-11-16 The Regents Of The University Of California Devices for administration of naked polynucleotides which encode biologically active peptides
US5597569A (en) * 1993-10-25 1997-01-28 Bristol-Myers Squibb Company Bryodin 2 a ribosome-inactivating protein isolated from the plant Bryonia dioica
DE69433820T2 (de) 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
AU735459B2 (en) 1997-01-30 2001-07-12 University Of Virginia Patent Foundation Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
EP1082141B1 (en) * 1998-05-23 2005-09-14 Leiden university medical center Cd40 binding antibodies and ctl peptides for treating tumors
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
JP2003527861A (ja) * 2000-03-16 2003-09-24 ジェネンテック・インコーポレーテッド 増強した抗血液凝固能を持つ抗組織因子抗体
AU3957602A (en) * 2000-12-14 2002-06-24 Genentech Inc Bacterial host strains
ES2347959T3 (es) * 2003-02-20 2010-11-26 Seattle Genetics, Inc. Conjugados de anticuerpos anti-cd70-farmaco y su uso para el tratamiento del cancer.
AU2004297616B2 (en) * 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
US20060003412A1 (en) * 2003-12-08 2006-01-05 Xencor, Inc. Protein engineering with analogous contact environments
EP1807451A2 (en) * 2004-08-03 2007-07-18 Dyax Corporation Hk1-binding proteins
DE602006012839D1 (de) * 2005-05-20 2010-04-22 Genentech Inc Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit
JP5027804B2 (ja) * 2005-05-26 2012-09-19 シアトル ジェネティクス，インコーポレーテッド ヒト化抗ｃｄ４０抗体およびその使用方法

Also Published As

Publication number Publication date
DE602006017690D1 (de) 2010-12-02
KR100991010B1 (ko) 2010-10-29
CA2609269A1 (en) 2006-11-30
NO20076404L (no) 2008-02-13
US20140193405A1 (en) 2014-07-10
JP2008541733A (ja) 2008-11-27
JP5027804B2 (ja) 2012-09-19
EP1885399B1 (en) 2010-10-20
AU2006249305A1 (en) 2006-11-30
US20130023047A1 (en) 2013-01-24
CN101237882A (zh) 2008-08-06
ECSP078026A (es) 2008-03-26
ES2354865T3 (es) 2011-03-18
BRPI0610470A2 (pt) 2010-06-22
RU2407544C2 (ru) 2010-12-27
MA29595B1 (fr) 2008-07-01
WO2006128103A3 (en) 2007-01-18
CA2609269C (en) 2014-08-05
CN101237882B (zh) 2012-08-15
EP1885399A4 (en) 2009-04-22
US20130315900A1 (en) 2013-11-28
IL187594A0 (en) 2008-03-20
US8303955B2 (en) 2012-11-06
KR20080030958A (ko) 2008-04-07
NO341793B1 (no) 2018-01-22
EP1885399A2 (en) 2008-02-13
PL1885399T3 (pl) 2011-04-29
US8492531B2 (en) 2013-07-23
WO2006128103A2 (en) 2006-11-30
RU2007148932A (ru) 2009-07-10
US20090181015A1 (en) 2009-07-16
ATE485057T1 (de) 2010-11-15
AU2006249305B2 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
CR9562A (es) Anticuerpos anti-cd40 humanizados y sus metodos de uso
LTPA2017040I1 (lt) Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui
ES2523194T3 (es) Anticuerpo monoclonal humano específico para cada tumor
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
AR052284A1 (es) Variantes de un anticuerpo y usos de las mismas
NO20085104L (no) Antagonistisk anti-humant CD40-monoklonalt antistoff
IL244803B (en) Human anti-beta antibodies and their use
DK1716181T3 (da) CDR-reparerede antistoffer
ECSP088733A (es) Anticuerpos anti-5t4 y usos de los mismos
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
EA200802182A1 (ru) Модифицированные гуманизированные антитела против интерлейкина-18
PE20120079A1 (es) Moleculas de anticuerpos mejoradas
EA200702064A1 (ru) Новое анти-plgf антитело
NO20071436L (no) Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater
ATE517183T1 (de) Monoklonaler antikörper gegen cd20
EA201070695A1 (ru) Молекулы гуманизированных антител, специфичных к il-31
CL2007003622A1 (es) Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
HK1151305A1 (zh) 用於治療癌症的針對密蛋白- 的單克隆抗體
UA94452C2 (ru) Гуманизированные моноклональные антитела к фактору роста гепатоцитов
UA92504C2 (en) Anti-myostatin monoclonal antibody
NZ611269A (en) Neutralizing anti-ccl20 antibodies
DK1758610T3 (da) Fremgangsmåder til behandling af cancer ved hjælp af IL-21 og monoklonal antistofterapi
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
DK1641828T3 (da) Anti-HGF-R-antistoffer og deres anvendelse
ATE546524T1 (de) Verfahren zur herstellung aktiver scfv-antikörper und bibliotheken dafür

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)